On October 20, 2026 HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM:HCM; HKEX:13) reported that further to its announcement on September 3, 2026 and following the completion of customary closing conditions including antitrust regulatory reviews, the exclusive development and license agreement between HUTCHMED Limited (a subsidiary of the Company) and a subsidiary of GSK plc ("GSK") has closed. The agreement grants the GSK subsidiary worldwide rights excluding Mainland China, Hong Kong, Macau and Taiwan to develop and commercialize HMPL-A830.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
This first-in-class Antibody-Targeted Therapy Conjugate ("ATTC") drug candidate comprises a highly selective and potent Kirsten rat sarcoma ("KRAS") small molecule inhibitor payload conjugated to an anti-epidermal growth factor receptor ("EGFR") antibody. Colorectal, pancreatic and lung cancers have the highest incidence of patients with KRAS-altered tumors, who often lack safe and durable KRAS therapy. HMPL-A830 is designed to address this need by delivering a KRAS inhibitor directly to EGFR-expressing tumors, while simultaneously blocking EGFR and KRAS signaling to enhance efficacy, durability, and tolerability. The Phase Ia part of a global clinical trial of HMPL-A830 in patients with unresectable, advanced or metastatic solid tumors in China and the US was initiated in September 2026 (clinicaltrials.gov identifier NCT07718581).
Under the terms of the agreement, HUTCHMED Limited is responsible for the global Phase I development program. The GSK subsidiary will be responsible for all subsequent clinical development and commercialization activities in its territory. Following the closing of the exclusive license agreement, HUTCHMED Limited expects to receive US$110 million upfront payment shortly, and may receive additional development, regulatory and commercial milestone payments of up to a total of US$1.185 billion, as well as tiered royalties on annual net sales.
(Press release, Hutchison China MediTech, OCT 20, 2026, View Source [SID1234673609])